相关临床试验
339
34 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1998
进行中（未招募）
25
7.4%
已完成
223
65.8%
Enrolling By Invitation
2
0.6%
尚未招募
7
2.1%
招募中
52
15.3%
暂停
1
0.3%
终止
16
4.7%
Unknown
5
1.5%
撤回
8
2.4%
暂无批准数据
- A first-in-class PET radiotracer, 18F-OXD-2314, demonstrated elevated uptake in grey-white matter junctions of retired athletes with suspected CTE compared to healthy controls. - The tracer also showed binding in all post-mortem CTE tissue examined, providing early biological confirmation of its ability to detect tau pathology specific to CTE. - Separately, the Alzheimer's-associated protein eMTBR-tau243 showed stage-specific increases in blood samples from donors with confirmed CTE pathology, rising from Stage I to Stage IV disease. - Both approaches could provide the first accurate in-life diagnostic biomarkers for CTE, potentially enabling clinical trials and offering patients clarity within the next two years.
- A CAMH study provides the first direct evidence of dopamine neuron loss in long COVID, with PET scans showing significantly reduced dopamine transporter markers across all major striatal regions. - Lower dopamine markers correlated with specific symptoms: reduced motivation linked to ventral striatum, slower movement to dorsal putamen, and poorer memory to caudate putamen. - A separate Finnish study found no evidence of widespread neuroinflammation in long COVID patients compared to healthy controls, though increased cellular activity in the hippocampus and amygdala was tied to anxiety and depression severity. - CAMH researchers plan a clinical trial evaluating dopamine-targeting medications, potentially shifting treatment strategies from anti-inflammatory approaches toward restoring dopamine function.
- An international research team led by CAMH has received nearly $800,000 in funding to advance a novel multiple sclerosis therapy that targets excitotoxicity to halt disease progression and repair nerve damage. - The experimental compound has demonstrated the ability to restore motor skills and repair myelin in animal models, even when administered after symptoms appeared. - The therapy could mark Canada's first regenerative treatment for MS, offering hope to restore previously lost functions in patients with the neurodegenerative disease. - The research is entering final preclinical testing stages to prepare for human clinical trials, with patent protection secured and industry partnerships being sought.
- Viatris has launched Gen-Clozapine orally disintegrating tablets in Canada, marking the first availability of this formulation for treatment-resistant schizophrenia patients. - The new formulation rapidly disintegrates on the tongue or can be chewed, providing an alternative to traditional tablets for patients who may need this option. - An estimated 25% to 30% of individuals with schizophrenia meet the criteria for treatment-resistant schizophrenia, making this the only approved antipsychotic for this condition. - The medication is available through the GenCAN patient support program, which currently supports more than 12,000 active patients across Canada.
